Hemorheological methods in drug research

Clinical Hemorheology and Microcirculation

Volumn 30, Issue 3-4, 2004, Pages 243-252

  Marton, Zsolt ^a   Halmosi, Robert ^a   Alexy, Tamas ^a   Horvath, Beata ^a   Toth, Ambrus ^a   Feher, Gergely ^a   Koltai, Katalin ^a   Kesmarky, Gabor ^a   Habon, Tamas ^a   Sumegi, Balazs ^a   Hideg, Kalman ^a   Toth, Kalman ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

2 MERCAPTO 4(3H) QUINAZOLINONE; 4 HYDROXYQUINAZOLINE; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CARVEDILOL; EPTIFIBATIDE; H 2545; H 2954; HO 2433; HO 2434; HO 3089; METOPROLOL; MEXILETINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIFEDIPINE; PROCAINAMIDE; PROPAFENONE; QUINAZOLINE DERIVATIVE; SCAVENGER; SOTALOL; TIMOLOL; TRIMETAZIDINE; TROLOX C; UNCLASSIFIED DRUG; VERAPAMIL;

ANTIOXIDANT ACTIVITY; BLOOD FLOW; BLOOD RHEOLOGY; CELL PROTECTION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG RESEARCH; DRUG SCREENING; ERYTHROCYTE; FILTRATION; HUMAN; HUMAN CELL; ISCHEMIA; MODEL; NORMAL HUMAN; OXIDATIVE STRESS; VALIDATION PROCESS; VASCULARIZATION;

ADENOSINE DIPHOSPHATE; ANTIOXIDANTS; BLOOD PLATELETS; CARBAZOLES; CARDIOTONIC AGENTS; COLLAGEN; EPINEPHRINE; ERYTHROCYTES; HEMORHEOLOGY; HUMANS; INDOLES; PLATELET AGGREGATION; PROPANOLAMINES;

EID: 3242740890     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. T. Alexy, A. Toth, Zs. Marton, B. Horvath, K. Koltai, G. Kesmarky, T. Kalai, K. Hideg, B. Sumegi and K. Toth, Inhibition of platelet aggregation by poly(ADP-ribose) polymerase inhibitors, J. Cardlovasc. Pharmacol., accepted for publication.
2. A. Chiarugi, Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited, Trends Pharmacol. Sci. 22 (2002), 122-129.
3. J.G. Coghlan, W.D. Flitter, C.D. Ilsley, A. Ress and T.F. Slater, Reperfusion of infarcted tissue and free radicals, Lancet 338 (1991), 1145-1146.
4. J.C. Docherty, B. Kuzio, J.A. Silvester, J. Bowes and C. Thiemermann, An inhibitor of poly(ADP-ribose) synthase reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischaemic rat heart, Br. J. Pharmacol. 127 (1999), 1518-1524.
5. B. Farkas, M. Magyarlaki, B. Csete, J. Nemeth, G. Rabloczky, S. Bernath, P.N. Literati and B. Sumegi, Reduction of acute photodamage in skin by topical application of a novel PARP inhibitor, Biochem. Pharmacol. 63 (2002), 921-932.
6. T. Habon, E. Szabados, G. Kesmarky, R. Halmosi, T. Past, B. Sumegi and K. Toth, The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals, Cardiovasc. Res. 52 (2001), 153-160.
7. B. Halliwell and J.M.C. Gutteridge, eds, Free Radicals in Biology and Medicine, Clarendon Press, Oxford, 1993.
8. R. Halmosi, Z. Berente, E. Osz, K. Toth, B. Literati-Nagy and B. Sumegi, Effect of poly-ADP-ribose-polymerase inhibitors on the ischemia-reperfusion induced oxidative cardiac injury and mitochondrial metabolism in Langendorff heart perfusion system, Mol. Pharmacol. 59 (2001), 1497-1505.
9. R. Halmosi, P. Deres, A. Toth, Z. Berente, T. Kalai, B. Sumegi, K. Hideg and K. Toth, Pyrroline based compounds in the prevention of oxyradical induced myocardial damage, J. Cardiovasc. Pharmacol. 40 (2002), 854-867.
10. O.H. Hankovszky, K. Hideg, I. Bodi and L. Frank, New antiarrhythmic agents. 2,2,5,5,-tetramethyl-3-pyrroline-3-carboxamides and 2,2,5,5,- tetramethylpyrrolidine-3-carboxamides, J. Med. Chem. 29 (1986), 1138-1152.
11. N. Hogg, Free radicals in disease, Semin. Reprod. Endocrinol. 16 (1998), 241-248.
12. T. Ide, H. Tsutsui, S. Kinugawa, H. Utsumi and A. Takeshita, Amiodarone protects cardiac myocytes against oxidative injury by its free radical scaveging action, Circulation 100 (1999), 690-692.
13. H. Li, K.Y. Xu, L. Zhou, T. Kalai, J.L. Zweier, K. Hideg and P. Kuppusamy, A pyrroline derivative of mexiletine offers marked protection against ischemia/reperfusion-induced myocardial contractile dysfunction, J. Pharmacol. Exp. Ther. 295 (2000), 563-571.
14. I.T. Mark and W.B. Weglicki, Comparative antioxidant activities of propanolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation, Circ. Res. 66 (1990), 1449-1452.
15. Zs. Marton, R. Halmosi, B. Horvath, T. Alexy, G. Kesmarky, J. Vekasi, I. Battyany, K. Hideg and K. Toth, Scavenger effect of experimental and clinically used cardiovascular drugs, J. Cardiovasc. Pharmacol. 38 (2001), 745-753.
16. S.A. Mousa, Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond, Drug. Discov. Today 4 (1999), 552-561.
17. P. Pacher, L. Liaudet, J.G. Mabley, K. Komjati and C. Szabo, Pharmacologic inhibition of poly(adenosine diphosphateribose) polymerase may represent a novel therapeutic approach in chronic heart failure, J. Am. Coll. Cardiol. 40 (2002), 1006-1016.
18. A.I. Schafer, Antiplatelet therapy, Am. J. Med. 101 (1996), 199-209.
19. R.A. Shankar, K. Hideg, J.L. Zweier and P. Kuppusamy, Targeted antioxidant properties of N-[(tetramethyl-3-pyrroline-3-carboxamido)-propyl] phthalimide and its nitroxide metabolite in preventing postischemic myocardial injury, J. Pharmacol. Exp. Ther. 292 (2000), 838-845.
20. E. Szabados, B. Literati-Nagy, B. Farkas and B. Sumegi, BGP-15, a nicotic amidoxime derivate, protects heart from ischemia-reperfusion injury through modulation of poly(ADP-ribose) polymerase activity, Biochem. Pharmacol. 59 (2000), 937-945.
21. P. Twomey, J. Taira, W. DeGraff, J.B. Mitchell, A. Russo, M.C. Krishna, O.H. Hankovszky, L. Frank and K. Hideg, Direct evidence for in vivo nitroxide free radical production from a new antiarrhythmic drug by EPR spectroscopy, Free Radic. Biol. Med. 22 (1997), 909-916.
22. Y.X. Xue, J. Arita, N.N. Aye and K. Hashimoto, Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide, N.-S. Arch. Pharmacol. 358 (1998), 649-656.
23. L. Virag and C. Szabo, The therapeutic potential of poly(ADP-ribose) polymerase inhibitors, Pharmacol. Rev. 54 (2002), 375-429.